Status
Conditions
Treatments
About
The purpose of this study is to assess the effectiveness and safety of the theanine for stress relief formulation versus placebo on stress, burnout component, mood and sleep
Full description
This is a double-blind, randomized, placebo-controlled study to evaluate the effects of a theanine for stress relief formulation on stress, burnout component, mood, and sleep in individuals who report occasional moderate or high levels of stress.
Participants will be asked to completed assessments and questionnaires as well as obtain a self saliva sample.
The primary objective is to evaluate the median change in response to the theanine formulation on stress from completed questionnaires, Perceived Stress Scale-14 (PSS-14) and the State Trait Anxiety Inventory (STAI) for stress.
The secondary objective is to evaluate the median change in response to the theanine formulation on stress from completed questionnaires, Depression, Anxiety and Stress Scale (DASS-21), Leeds Sleep Evaluation Questionnaires (LSEQ), Maslach Burnout Inventory General Survey (MBI-GS) and Short Form 36 Health Survey and Cortisol levels.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Not having the basic skills needed to operate a smartphone, tablet, or computer
Having smoked any cigarette, electronic cigarette, cigar, pipe, or used a recreational drug as well as any product containing cannabidiol (CBD) or tetrahydrocannabinol (THC) in the past 30 days prior to Screening
Having donated blood within 30 days before Screening
Having been diagnosed with dysphagia or difficulty swallowing
Having participated in another study within 30 days prior to Screening
Being pregnant, planning on becoming pregnant during study participation or refusing to indicate willingness to use a medically acceptable form of birth control, if applicable, during study participation, or breast feeding
Are participating in a stress management program and will not for the duration of the study participation
Unable to avoid any form of intense exercise or a significant change in exercise routine during the day of saliva specimen collection
Currently taking any supplements containing L-theanine or D-theanine within the past 30 days before Screening
Currently taking supplements including melatonin, 5-hydroxytryptophan, Calamus, California poppy, St. John's wort, S-adenosylmethionine (SAM-E), catnip, hops, kava, valerian, Jamaican dogwood, skullcap, yerba mansa, Hawaiian baby woodrose, L-theanine, magnesium, or any other supplement for stress, burnout, mood, or sleep. These may preclude participation in the study dependent the judgment of the Study Investigator/Sub-Investigator
Having been diagnosed, received medical treatment, taking medications or supplements daily for the following medical condition(s):
Presence of active or recurring clinically significant conditions as follows:
Currently taking or having taken within the 30 days before Screening any hormone replacement therapy, except those utilized as a method of birth control and which have been taken for > 3 months with no anticipated change for the duration of the study period
Having had a surgical procedure or having an internal medical device which, in the judgment of the Study Investigator/Sub-Investigator, would preclude participation in the study
Currently consumes more than 4 standard alcoholic drinks per week for women and 7 drinks per week for men (a standard alcoholic drink is defined as one bottle/can of beer, one glass of wine, or one ounce of hard liquor)
Unable or unwilling to avoid consuming grapefruit juice or fresh grapefruit, Seville oranges, and tangelos for the duration of the study period
History of known or suspected substance abuse (e.g., alcohol, opiates, benzodiazepines, or amphetamines) 18 Having any other circumstance that may preclude study participation in the judgment of the Study Investigator/Sub-Investigator, including use of other nutritional supplements, which will be evaluated on a case-by-case basis
Primary purpose
Allocation
Interventional model
Masking
104 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Melanie Meade, BS; Dr. Steven Hirsh
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal